For assistance, contact your pharmacy representative: Phone:	(For providers only)
--	----------------------

Note: This form is intended for prescriber use only, if faxed, the fax must come from prescriber's office or hospital (may not be faxed by patient).

## **Breast and Ovarian Cancers**

		Prescri	iption/Pharma	cy Intake Form					
Pharmacy:									
Pharmacy Fax:		paribaria Offica Dationta L		harmacy Phone:					
Date Needed: PATIENT INFORMATION		scriber's Office  Patient's F	Home □Otner: _						_
Patient name:				DOB.			□Male	□Female	
Address:								omalo	
				State:		Zip code:			
Phone # (Daytime):				t (Evening):					
Insurance provider (Please in		ack of card):							_
ID#: CLINICAL ASSESSME		ALL costions to avoi	Phone #:	lling properintion		_ □Patient is	eligible for	Medicare	
☐ Patient is new to therapy				ming prescription					
ICD-10 code:			on:						
Weight:	 D □kg Date:	Height:	on	□in □cm Date:		BSA:		n	 n²
Allergies:									
Please indicate the documen	its(s) attached: □Failed the	rapies  Recent laboratory	results □Recent	t pathology report □Re	cent office notes	Copy of front	and back of	insurance c	ard
Breast Cancer:		Breast Cancer:			Ovaria	n Cancer:			
	Positive   Negative	Estrogen Receptor Statu		Positive ☐ Negative	BRCA	mutation	□Positiv	re □Negativ	/e
PIK2CA mutation □P	Positive □ Negative	HER2 Status		Positive ☐Negative					
		Progesterone Receptor	Status	Positive ☐ Negative					
Is patient postmenopausal?	□Yes □No								
Medication			Dose/Directi	ons/Frequency				Qty	Refills
□ Afinitor†	□ Ibrance <sup>†</sup>	□Kisqali†							
☐Kisqali Femara Co-Pack	, , , ,	□Lynparza tablets*							
□Piqray	□Talzenna	☐ Tykerb <sup>†</sup>							
□Verzenio†	□Xeloda								
☐ Other:									
†If prescribing Afinitor:	□Aromasin								
†If prescribing Ibrance:	□ Arimidex □ Aromasin								
†If prescribing Kisgali:	□ Arimidex □ Aromasin								
†If prescribing Tykerb:	□Femara								
†If prescribing Verzenio:	□Arimidex □Aromasin								
☐ MuGard	Other:								
□Akynzeo	□ Aloxi	□Anzemet							
,	Sancuso	□Zofran							
□Emend	□ Sancuso	□Z0IIdII							
Other:									
□Granix	□Leukine	□Neupogen							
□Neulasta	□Zarxio								
□Other:									
□Aranesp	□Procrit								
□Other:									
□Arixtra	□Fragmin								
□Heparin	□Lovenox								
□ Other:									
					* Available	e at select heal	th system p	harmacy loc	ations only.
PRESCRIBER INFORM	MATION								
Prescriber's name:			_ ,	r:					
Address:			_ City:		State:	Zip code:			_
Office contact:			_ Phone:		Fax:				
Email:				ll:		thod of contact			ax
State license #:	DEA #:			I					
In order for a brand name prod I certify that the above therapy									ure.
Dispen	nse as written		Subst	itution permitted				Date	

The prescriber is to comply with his/her state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

The document(s) accompanying this transmission may contain confidential health information that is legally protected. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless permitted or required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Drug names are the property of their respective owners.

©2022 All rights reserved.

092922